Table 1.

Baseline characteristics at collection of cfDNA

Characteristic (n = 62)
Age
 Median (IQR)72 (49–92)
Gleason score, n (%)
 6–714 (23)
 8–1038 (61)
 Unknown10 (16)
Disease sites, n (%)
 Bone60 (97)
 Lymph nodes33 (53)
 Visceral8 (13)
ECOG, n (%)
 0–141 (66)
 ≥221 (34)
Laboratory
 Hemoglobin (median, g/L; IQR)122 (108–128)
  ≤100, n (%)12 (19)
 LDH (median, U/L; IQR)209 (174–316)
  Elevated (>250), n (%)26 (42)
 ALP (median, U/L; IQR)144 (93–320)
  Elevated (>160), n (%)30 (48)
 Albumin (median, g/L; IQR)39 (32–41)
  Low (<35), n (%)14 (23)
  Normal, n (%)33 (53)
  Unknown, n (%)15 (24)
Current treatment
 Abiraterone acetate29 (47)
 Enzalutamide19 (31)
 Bicalutamide6 (10)
 Prednisone3 (5)
 Docetaxel3 (5)
 Other2 (3)
Outcomes on current treatment
 Best PSA response
  PSA decline ≥ 50%26 (42)
  PSA decline < 50%20 (32)
  No PSA decline16 (26)
 Median treatment duration (mo)5.4
All treatments received
 Abiraterone acetate46 (74)
 Enzalutamide19 (31)
 Docetaxel33 (53)
 Orteronel4 (6)
 Bicalutamide58 (94)
 Flutamide10 (16)
 Nilutamide10 (16)
 Other27 (44)